Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.52 |
| ▸ | AR | P10275 | 6/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694692 | 0.86 | CA1 (0.44) | IMPDH2IMPDH1ARTRPV4KDM4E | |
| SCHEMBL29489135 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL151936 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL11193357 | 0.83 | IMPDH2 (0.61) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL11228244 | 0.80 | IMPDH2 (0.59) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL16917824 | 0.78 | IMPDH2 (0.57) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL5572138 | 0.77 | SLC6A4 (0.33) | IMPDH2IMPDH1KDM4EALDH1A1GAA | |
| SCHEMBL3251429 | 0.77 | ALDH1A1 (0.36) | IMPDH2IMPDH1SLC22A12KDM4EALDH1A1 | |
| SCHEMBL737625 | 0.77 | SLC6A4 (0.33) | IMPDH2IMPDH1KDM4EALDH1A1GAA | |
| SCHEMBL6562728 | 0.77 | HPRT1 (0.46) | KDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240124433-A1 | Organic Compound And Organic Light-Emitting Device Comprising Same | P&H TECH CO., LTD (KR) | 2024-04-18 | — | — | US | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-116724684-A | Organic compound and organic light emitting device comprising the same | 株式会社P&H TECH | 2023-09-08 | — | — | CN | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20060142387-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-06-29 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1636167-A2 | 1-AMINONAPHTHALENES AS MODULATORS OF ANDROGEN, GLUCOCORTICOID, MINERALOCORTICOID AND PROGESTERONE RECEPTORS | SmithKline Beecham Corporation (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004110978-A2 | 1-AMINONAPHTHALENES AS MODULATORS OF ANDROGEN, GLUCOCORTICOID, MINERALOCORTICOID AND PROGESTERONE RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | IMPDH2 4239/4885IMPDH1 4294/4885AR 1/4885 |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | IMPDH2 777/4885IMPDH1 717/4885AR 2/4885 |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | IMPDH2 1105/4885IMPDH1 941/4885AR 2726/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | IMPDH2 351/4885IMPDH1 280/4885AR 3300/4885 |
| US-20240124433-A1 | Organic Compound And Organic Light-Emitting Device Comprising Same | VAPA, ICMT, ORMDL3 | IMPDH2 1516/4885IMPDH1 1777/4885AR 3710/4885 |
| US-20060142387-A1 | Chemical compounds | NR3C2, NR5A1, NR3C1 | IMPDH2 3262/4885IMPDH1 3635/4885AR 4/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | IMPDH2 16/4885IMPDH1 3/4885AR 1479/4885 |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | IMPDH2 1105/4885IMPDH1 941/4885AR 2726/4885 |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | IMPDH2 1166/4885IMPDH1 1088/4885AR 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.